Key Notes on Pembrolizumab and Docetaxel Combination Therapy for Metastatic Castration-Resistant Prostate Cancer. Thoman ME, Salari K. Eur Urol 2022 Apr 5. pii: S0302-2838(22)01787.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Thoman ME, Salari K. Key Notes on Pembrolizumab and Docetaxel Combination Therapy for Metastatic Castration-Resistant Prostate Cancer. Eur Urol 2022 Apr 5. pii: S0302-2838(22)01787.
PMID: 35396162